a) full control braking trial with 0% of LC probability for Model-1

a) full control braking trial with 0% of LC probability for Model-1

Frontiers Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials

Theoretical Performance Analysis

Pharmaceutics, Free Full-Text

Optimod-AM 9300 V1.0 Operating Manual - Radikal

American Society for Clinical Pharmacology and Therapeutics - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library

The interpretation of computational model parameters depends on the context

Frontiers Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer

Carbon Monoxide Signaling: Examining Its Engagement with Various Molecular Targets in the Context of Binding Affinity, Concentration, and Biologic Response

Context Matters: Emotional Sensitivity to Probabilities and the Bias for Action in Cancer Treatment Decisions - Heather P. Lacey, Steven C. Lacey, Prerna Dayal, Caroline Forest, Dana Blasi, 2023

Nanofiber-Based Systems for Stimuli-Responsive and Dual Drug Delivery: Present Scenario and the Way Forward